Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

Next Previous
Trial Profile

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inebilizumab (Primary) ; Corticosteroids; Immune globulin; Methylprednisolone
  • Indications Anti-N-methyl-D-aspartate-receptor-encephalitis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms ExTINGUSH

Most Recent Events

  • 01 Jul 2025 Planned End Date changed from 31 Aug 2026 to 30 Sep 2028.
  • 01 Jul 2025 Planned primary completion date changed from 31 Oct 2025 to 30 Sep 2028.
  • 06 Sep 2022 Planned End Date changed from 30 Aug 2026 to 31 Aug 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top